| CAS NO: | 183718-75-4 |
| 包装 | 价格(元) |
| 10mg (solution) | 电议 |
| 50mg (solution) | 电议 |
| 100mg (solution) | 电议 |
| Physical Appearance | A solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. |
| Storage | Store at -20°C |
| M.Wt | 395.6 |
| Cas No. | 183718-75-4 |
| Formula | C26H37NO2 |
| Synonyms | 3-HPAA |
| Solubility | ≤20mg/ml in DMSO;20mg/ml in dimethyl formamide |
| Chemical Name | N-(3-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide |
| Canonical SMILES | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Nc1cccc(O)c1 |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
IC50: 2 μM
N-(3-hydroxyphenyl) -Arachidonoyl amide, also known as 3-HPAA, is an analog of AM404 (N-(4-hydroxyphenyl)-arachidonoyl amide), a selective inhibitor of carrier-mediated transport of arachidonoyl ethanolamide. 3-HPAA, metabolized by both cyclooxygenase (COX) -1 and COX-2, is an irreversible and selective inhibitor of COX-2 with an IC50 value of 2 M. 3-HPAA can be efficiently oxygenated to prostaglandin and hydroxyeicosatetraenoate products by prostaglandin endoperoxide synthase (PGHS) -2. It appears that 3-HPAA can be converted by PGHS-1 in a similar manner.
COX enzymes play elaborate roles in human physiology and pathology, involving neuronal, immune, renal, cardiovascular, gastrointestinal, and reproductive systems. COX enzymes are blocked by aspirin and a wide variety of other non-steroidal anti-inflammatory drugs, which makes them clinically important [1]. COX-2, overexpressed in cancer cells, promotes tumorigenesis and induces neo-angiogenesis. Additionally, it plays an important role in inflammation and pyrexia.
In vitro: Up to now, in vitro study of 3-HPAA is still in the development stage.
In vivo: Up to now, in vivo study of 3-HPAA is still in the development stage.
Reference:
[1]. Fitzpatrick, F. Cyclooxygenase Enzymes: Regulation and Function. Current Pharmaceutical Design. 2004; 10(6): 577-588.
m.cnreagent.com